UPDATE 1-Omrix gets FDA nod to use cryo in manufacturing process

(Reuters) - On Oct. 11, Omrix announced a long-term supply agreement
with Talecris for cryo under which Omrix committed to certain
minimum purchases and obtained a right of first refusal to
additional supply of cryo.




Omrix uses Cryoprecipitate or cryo to make BAC, the
fibrinogen component of its marketed surgical tissue adhesives,
Evicel and Quixil.


Read more at Reuters.com Government Filings News